Advertisement
Document › Details
Forbion Capital Partners. (3/13/18). "Press Release: Forbion Leads $19 Million Series B Financing of Escalier Biosciences to Advance Its Topical and Systemic RORgammat Therapies for Psoriasis and other Autoimmune Diseases".
Forbion, one of the leading European life science venture capital firms, today announced that it led the $19 million Series B financing of Escalier Biosciences BV, a privately held biopharmaceutical company based in Nijmegen, The Netherlands. Escalier Biosciences is developing both oral and topical ROR?t drug candidates for psoriasis and other autoimmune diseases.
The financing round was completed by existing investors, New Science Ventures and BioGeneration Ventures and will be used to advance Escalier’s RORyt compounds through human proof-of-concept studies.
The nuclear hormone receptor RORyt has emerged as the “master” regulator of Th17 cell differentiation and the production of pro-inflammatory cytokines, such as IL-17A and IL-17F. Increased production of these cytokines has been linked to the pathophysiology of psoriasis. Small molecule inhibitors of ROR?t have been shown to reduce production of IL-17 in immune cells and are promising therapies for psoriasis and other autoimmune conditions.
Escalier expects its topical compound to enter the clinic in mid-2018.
“Escalier’s team has an impressive track record of developing novel compounds targeting diseases with significant unmet medical need,” stated Marco Boorsma, General Partner at Forbion who will join Escalier’s Board of Directors. “We are excited to participate in this financing with New Science Ventures and BioGeneration Ventures and in supporting Escalier’s efforts to develop best-in-class drugs for the treatment of psoriasis and other autoimmune diseases.”
“RORyt is a validated target for psoriasis and other autoimmune disorders and our drug candidates have the potential to provide the desired efficacy and safety in psoriasis patients that is currently unavailable with other topical or oral drugs,” said Raju Mohan, Ph.D., Chief Executive Officer of Escalier and previously CEO of Forbion’s portfolio company Akarna Therapeutics. “We are incredibly fortunate to have such a supportive syndicate of investors that share our passion in developing novel therapies for challenging targets, such as “RORyt."
Record changed: 2023-06-05 |
Advertisement
More documents for Forbion (Group)
- [1] NewAmsterdam Pharma Company N.V.. (4/1/24). "Press Release: NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer". Naarden & Miami, FL....
- [2] Engrail Therapeutics, Inc.. (3/19/24). "Press Release: Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies". San Diego, CA....
- [3] Forbion Capital Partners. (1/9/24). "Press Release: Forbion Portfolio Company Aiolos Bio, Inc. (Aiolos) to Be Acquired by GSK for up to $1.4 Billion"....
- [4] Kynexis B.V.. (11/7/23). "Press Release: Kynexis Launched to Advance Precision Therapeutics for Brain Diseases". Naarden....
- [5] Mariana Oncology Inc.. (9/7/23). "Press Release: Mariana Oncology Announces $175 Million Series B Financing". Watertown, MA....
- [6] AAVantgarde Bio S.r.l.. (6/6/23). "Press Release: AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic". Milan....
- [7] Forbion Capital Partners. (4/19/23). "Press Release: Forbion Raises €1.35 Billion across Two Funds". Espoo....
- [8] Noema Pharma AG. (3/7/23). "Press Release: Noema Pharma Raises CHF 103 million (USD 112 million) in Series B Financing Round Led by Forbion and Jeito Capital". Basel....
- [9] Inversago Pharma Inc.. (10/19/22). "Press Release: Inversago Pharma Announces Appointment of Ed Mathers, BSc and Nanna Lüneborg, PhD, MBA to its Board of Directors". Montréal, QC....
- [10] F2G Ltd.. (8/4/22). "Press Release: F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim". Manchester....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top